Arrien Investments, Inc. Eli Lilly & CO Transaction History

Arrien Investments, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 10, 2025	SELL	$725.72 - $929.72 $47,171 - $60,431	-65 Reduced 20.9%	246 $203 Million
Q4 2024 Feb 10, 2025	BUY	$727.2 - $932.06 $178,891 - $229,286	246 New	246 $203 Million
Q3 2024 Apr 10, 2025	SELL	$772.14 - $960.02 $20,847 - $25,920	-27 Reduced 7.99%	311 $276 Million
Q2 2024 Apr 10, 2025	BUY	$724.87 - $909.04 $66,688 - $83,631	92 Added 37.4%	338 $306 Million
Q1 2024 Apr 10, 2025	SELL	$592.2 - $792.28 $78,762 - $105,373	-133 Reduced 28.24%	338 $263 Million

Q3 2023 Apr 10, 2025	SELL	$434.7 - $599.3 $14,345 - $19,776	-33 Reduced 6.55%	471 $253 Million
Q2 2023 Apr 10, 2025	SELL	$350.74 - $468.98 $86,282 - $115,369	-246 Reduced 32.8%	504 $236 Million
Q1 2023 Apr 10, 2025	BUY	$310.63 - $364.82 $156,557 - $183,869	504 Added 204.88%	750 $258 Million

4,504

754M

14.8M

16.9M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $971B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Arrien Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Arrien Investments, Inc. with notifications on news.